Glucokinase and glucokinase activator

Abstract

Glucokinase (GK) plays a pivotal role in glucose homeostasis as the glucose sensor in the pancreas and liver. Loss of function of GK results in hyperglycemia, and gain of function causes congenital hyperinsulinemic hypoglycemia. We speculate that the progressive loss of GK at both messenger RNA (mRNA) and protein levels in the islets and liver would be the key mechanism for Type 2 diabetes (T2D) pathogenesis. The development of GK activator (GKA) as an anti-diabetic drug has been endeavored for several decades. The failure of the early development of GKAs is due to the limitation of understanding the mode of GKA action. The success of dorzagliatin in the treatment of T2D has brought new hope for GK in setting a good model for repairing the underlying defects in the pancreatic islets and liver of T2D patients.

Keywords

glucokinases / glucokinase activator / Type 2 diabetes / pancreatic β cells / liver / glucose homeostasis

References

[1] Matschinsky FM, Liang Y, Kesavan P et al. Glucokinase as pancreatic β-cell glucose sensor and diabetes gene. J Clin Invest 1993;92:2092–8.

[2] Campbell JE, Newgard CB. Mechanisms controlling pancreatic islet cell function in insulin secretion. Nat Rev Mol Cell Biol 2021;22:142–58.

[3] Matschinsky FM. Banting lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 1996;45:223–41.

[4] Henquin JC. Regulation of insulin secretion: a matter of phase control and amplitude modulation. Diabetologia 2009;52:739–51.

[5] Davis EA, Cuesta-Munoz A, Raoul M et al. Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia 1999;42:1175–86.

[6] Basco D, Zhang Q, Salehi A et al. α-Cell glucokinase suppresses glucose-regulated glucagon secretion. Nat Commun 2018;9:546.

[7] Zhang Q, Ramracheya R, Lahmann C et al. Role of K_ATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab 2013;18:871–82.

[8] Moede T, Leibiger B, Vaca Sanchez P et al. Glucokinase intrinsically regulates glucose sensing and glucagon secretion in pancreatic alpha cells. Sci Rep 2020;10:20145.

[9] Lu B, Kurmi K, Munoz-Gomez M et al. Impaired β-cell glucokinase as an underlying mechanism in diet-induced diabetes. Dis Model Mech 2018;11:dmm033316.

[10] Kim YB, Iwashita S, Tamura T et al. Effect of high-fat diet on the gene expression of pancreatic GLUT2 and glucokinase in rats. Biochem Biophys Res Commun 1995;208:1092–8.

[11] van Schaftingen E, Veiga-da-Cunha M, Niculescu L. The regulatory protein of glucokinase. Biochem Soc Trans 1997;25:136–40.

[12] Krssak M, Brehm A, Bernroider E et al. Alterations in postprandial hepatic glycogen metabolism in type. Diabetes 2004;53:3048–56.

[13] Jiang MH, Fei J, Lan MS et al. Hypermethylation of hepatic Gck promoter in ageing rats contributes to diabetogenic potential. Diabetologia 2008;51:1525–33.

[14] Haeusler RA, Camastra S, Astiarraga B et al. Decreased expression of hepatic glucokinase in type 2 diabetes. Mol Metab 2015;4:222–6.

[15] Li C, Liu C, Nissim I et al. Regulation of glucagon secretion in normal and diabetic human islets by γ-hydroxybutyrate and glycine. J Biol Chem 2013;288:3938–51.

[16] Herrmann C, Göke R, Richter G et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995;56:117–26.

[17] Jetton TL, Liang Y, Pettepher CC et al. Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut. J Biol Chem 1994;269:3641–54.

[18] Gribble FM, Williams L, Simpson AK et al. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 2003;52:1147–54.

[19] Christensen M, Vedtofte L, Holst JJ et al. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011;60:3103–9.

[20] Sun EW, De Fontgalland D, Rabbitt P et al. Mechanisms controlling glucose-induced GLP-1 secretion in human small intestine. Diabetes 2017;66:2144–9.

[21] Matschinsky FM, Davis EA. The distinction between ‘glucose setpoint’, ‘glucose threshold’ and ‘glucose sensor’ is critical for understanding the role of the pancreatic cell in glucose homeostasis. Front Diabetes 1998;14:14–29.

[22] Chen L, Zhang J, Sun Y et al. A phase I open-label clinical trial to study drug-drug interactions of dorzagliatin and sitagliptin in patients with type 2 diabetes and obesity. Nat Commun 2023;14:1405.

[23] Muscelli E, Mari A, Casolaro A et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340–8.

[24] Chen L, Zhang J, Yang R et al. Glucokinase activator dorzagliatin (HMS5552) regulates GLP-1 release in T2D patients and is synergistic with sitagliptin and empagliflozin in optimizing β-cell function. ADA Poster 2021:117–LB.

[25] Svendsen B, Larsen O, Gabe MBN et al. Insulin secretion depends on intra-islet glucagon signaling. Cell Rep 2018;25:1127–34.e2.

[26] Zhu L, Dattaroy D, Pham J et al. Intraislet glucagon signaling is critical for maintaining glucose homeostasis. JCI Insight 2019;5:e127994.

[27] Matschinsky FM. GKAs for diabetes therapy: why no clinically useful drugs after 2 decades of trying? Trends in Pharm Sci 2013;34:90–9.

[28] Meininger GE, Scott R, Alba M et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 2011;34:2560–6.

[29] Eiki J, Nagata Y, Futamura M et al. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. Mol Pharmacol 2011;80:1156–65.

[30] Davis EA, Cuesta-Muñoz A, Raoul M et al. Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia 1999;42:1175–86.

[31] Chen L, Shan Y, Jin X et al. Dorzagliatin differentiates from early generation of glucokinase activators: an enzyme kinetics study. Diabetes 2019;68:1151–P.

[32] Wang P, Liu H, Chen L et al. Effects of a novel glucokinase activator, HMS5552, on glucose metabolism in a rat model of type 2 diabetes mellitus. J Diabetes Res 2017;2017: 5812607.

[33] Zhu XX, Zhu DL, Li XY et al. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: a 28-day treatment study using biomarker-guided patient selection. Diabetes Obes Metab 2018;20:2113–20.

[34] Zhu D, Gan S, Liu Y et al. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diabetes Endocrinol 2018;6:627–36.

[35] Zhu D, Li X, Ma J et al. Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 2022;28:965–73.

[36] Yang W, Zhu D, Gan S et al. Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 2022;28:974–81.

[37] RISE Consortium. Lack of durable improvements in β-cell function following withdrawal of pharmacological interventions in adults with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care 2019;42:1742–51.

[38] Taylor R, Al-Mrabeh A, Zhyzhneuskaya S et al. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery. Cell Metab 2018;28:547–56.e3.

RIGHTS & PERMISSIONS

2023 The Author(s) 2023. Published by Oxford University Press on behalf of Higher Education Press.